International Investment Afternoon (London)

A showcase of international investment opportunities in conjunction with our partners at International Deal Gateway.

Keynote from Dr. James Tansey, PhD. | Kilmat X Developments

James Tansey is a serial entrepreneur with two decades of experience in environmental and carbon markets. He is also a leading academic focused on clean energy strategy, impact investing and innovation having worked at the Saïd Business School in Oxford and the University of British Columbia's Sauder School of Business, where he has advised the BC and Federal governments on clean energy strategy and social enterprise. In his previous company, NatureBank, James established two of the world’s largest carbon projects and secured the world's first carbon-neutral Olympics in 2010 in Vancouver.

Klimat X is a Canadian company listed on the TSX:V that develops large scale carbon credit projects focused on nature-based solutions including reforestation, forest , agriculture and mangrove projects. The company takes a jurisdictional approach, working with national and sub-national governments in Sierra Leone, Mexico, Suriname and Guyana to secure the development rights to invest in large scale conservation and restoration projects. By working upstream, the company is able to manage the quality of the projects to meet the needs of large downstream voluntary market buyers, who are highly focused on securing quality carbon credits to meet net zero obligations. 

Presentations from:

Nick Blitterswyk | UGE International

Nick founded UGE in 2008 and has led the company as CEO ever since. In the early days, Nick and his team worked on finding economical use cases for clean energy technologies while the industry was still in its infancy, building projects ranging from wind and solar microgrids in remote locations, to lighting the Eiffel Tower with renewable energy. Over time, UGE turned its focus to solar and battery storage project development in the U.S. Raised on a Canadian nature reserve, Nick is a Fellow of the Society of Actuaries with previous experience at JPMorgan and AIG.    

UGE is working to make renewable energy accessible and affordable for all. As a developer, owner, and operator of mid-scale, community-focused solar and energy storage projects, we’re helping build a renewable energy future that is equitable and secure. Our develop-to-own model delivers faster project completion, better economics for our clients, and improved shareholder returns. Leaning on more than a decade of experience across 700 solar projects totaling over 500 megawatts, we’re proud to be making a significant impact on the world’s transition to clean energy, and we’re just getting started.  

Manolo Zuniga, Doug Urch | PetroTal

Mr Zuniga comes from a decorated oil and gas family in Peru, when is father drilled some of the first oil wells in northern Peru paving the way for major oil recoveries and active block creation years later. Mr. Zuniga is the current founder, director and CEO of PetroTal since inception of the Company and has successfully lead the extraction of over 12 million barrels of oil from Block 95 in just over five years. Mr. Zuniga started his career with Occidental Petroleum Corp in Peru and was the former founder and CEO of BPZ Energy helping shape and promoting oil and gas policy in Peru for over 30 years.

PetroTal is a publicly traded, tri‐quoted (TSX: TAL, AIM: PTAL and OTCQX: PTALF) oil and gas development and production Company domiciled in Calgary, Alberta, focused on the development of oil assets in Peru. PetroTal's flagship asset is its 100% working interest in Bretana oil field in Peru's Block 95 where oil production was initiated in June 2018. In early 2022, PetroTal became the largest crude oil producer in Peru. The Company's management team has significant experience in developing and exploring for oil in Peru and is led by a Board of Directors that is focused on safely and cost effectively developing the Bretana oil field. It is actively building new initiatives to champion community sensitive energy production, benefiting all stakeholders.

Dr. Philip Toleikis, Christopher Barnes | Sernova 

Dr. Philip M. Toleikis has been President, Chief Executive Officer, and a Director of Sernova Corp. since 2009. Dr. Toleikis has guided the development of Sernova’s integrated Cell Pouch System cell therapy platform in the pursuit of establishing a ‘functional cure’ for chronic diseases, such as diabetes, thyroid and rare diseases. Dr. Toleikis has contributed to Sernova’s core intellectual property development and secured in-licensing agreements and acquisition of Sernova’s core technologies, including most recently iPSC stem cell-derived and cellular immune protection technologies. Prior to joining Sernova, Dr. Toleikis was VP, R&D at Angiotech Pharmaceuticals, Inc., which developed and partnered with Boston Scientific in commercializing one of the first drug-eluting coronary stents. He obtained his Ph.D. in the Department of Medicine, Pharmacology and Therapeutics from the University of British Columbia, his M.Sc. at the University of Michigan, and B.A. at the University of Vermont.
 
Chris has worked in financial services for 23 years, first as an investor relations consultant, then as the investor relations officer for Extendicare Inc., a large North American nursing home company listed on both the TSX and NYSE. Subsequently, Chris moved directly into capital markets as an IIROC registered institutional salesperson with three Toronto-based investment boutiques, including Fraser Mackenzie, Octagon Capital, and Pace Securities covering accounts in Canada, the United States, and Europe. Chris holds a bachelor’s degree in English and Political Science from Laurentian University plus he completed the Richard Ivey School of Business at the University of Western Ontario, Strategic Investor Relations diploma.

Sernova Corp. is a clinical-stage biotechnology company developing therapeutic cell technologies to deliver a ‘functional cure’ for chronic diseases, including insulin-dependent diabetes (T1D), hypothyroid disease and hemophilia A. The Cell Pouch SystemTM, is a novel implantable medical device housing immune protected therapeutic cells which produce needed proteins and hormones to treat disease. Sernova’s T1D islet Phase 1/2 clinical study (University of Chicago) has already demonstrated the first three long-term diabetic patients insulin free for up to three years so far.  Sernova/Evotec entered into a partnership to develop an off-the-shelf iPSC islet therapy  planned for clinical trials in 2024, providing the potential to treat millions of patients with T1D and T2D.

Jeremy Sobotta | Perimeter Medical

Prior to joining Perimeter, Mr. Sobotta was the controller for the orthopaedics division of Smith and Nephew, and from 2008-2019, he held roles of increasing responsibility at Stryker including internal audit, finance transformation, commercial excellence, financial planning and analysis, and ultimately leading finance for their surgical business unit.  Mr. Sobotta brings to the role diverse medical device commercialization experience having lived and worked in North America, Europe, and Africa supporting commercial organizations across a wide range of medical technology including capital equipment, robotics and implants. 

Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Greg Reid | Kraken Robotics Inc.

Mr. Reid was Kraken’s CEO & President after being promoted on January 1, 2023 from COO. Prior to the COO role, Mr. Reid was the CFO from June 2015 to July 2019. Mr. Reid is a seasoned executive with over twenty years of finance, investment, and business development experience, predominantly focused on the technology sector. Mr. Reid was a founding partner of Wellington West Capital Markets Inc. and led the technology and clean technology research and then investment banking efforts until the sale of Wellington West Capital Inc. to National Bank Financial in 2011. Mr. Reid is a Charted Professional Accountant, Chartered Accountant, (CPA, CA) and Chartered Financial Analyst (CFA).

Kraken Robotics Inc. is a marine technology company dedicated to the production and sale of software-centric sensors, subsea batteries, and underwater robotic systems. It provides high-resolution 3D acoustic imaging solutions and services to enable clients to overcome the challenges in our oceans – safely, efficiently, and sustainably. Kraken Robotics is headquartered in Canada and has offices in North and South America and Europe. Kraken is ranked as a Top 100 marine technology company by Marine Technology Reporter.